Since the clinical cohort of glioma immunotherapy was scarce, the two well-known clinical cohorts including IMvigor 210 (urologic tumor patients treated with anti-PD-L1therapy) (Zhao et al., 2021) and Van Allen 2015 (melanoma patients treated with anti-CTLA-4 therapy) (Tu et al., 2022), which were previously used for assessing the relationship between target gene expressions and glioma immunotherapy, were selected in our present work. This evidence concerns the gene CTLA4 and central nervous system cancer.